Schaeffers Investment Research·2025-06-12 15:08Group 1 - CureVac NV's stock surged 32.2% to $5.37 following the announcement of BioNTech's acquisition of the company in an all-stock deal valued at $1.25 billion [1] - The merger is pending review by the German Economy Ministry, and CureVac's stock is trading at 52-week highs, breaking through the $5 resistance level [1] - Since the beginning of 2025, CureVac's equity has increased by 63.5% [1] Group 2 - CureVac's options market is experiencing significant activity, with trading volume reaching 45 times the average daily volume, particularly in the June 6 call options [2] - Short interest in CureVac has decreased by 14.1% over the past two weeks, although it still represents 4.4% of the stock's available float [2] - It would take over six days for short sellers to cover their positions based on CureVac's average trading pace [2]